{"id":62398,"date":"2026-02-19T19:29:05","date_gmt":"2026-02-19T13:59:05","guid":{"rendered":"https:\/\/matribhumisamachar.com\/en\/2026\/02\/19\/kiora-pharmaceuticals-to-present-at-oppenheimers-36th-annual-healthcare-life-sciences-conference\/"},"modified":"2026-02-19T19:29:05","modified_gmt":"2026-02-19T13:59:05","slug":"kiora-pharmaceuticals-to-present-at-oppenheimers-36th-annual-healthcare-life-sciences-conference","status":"publish","type":"post","link":"https:\/\/new.matribhumisamachar.com\/en\/2026\/02\/19\/kiora-pharmaceuticals-to-present-at-oppenheimers-36th-annual-healthcare-life-sciences-conference\/","title":{"rendered":"Kiora Pharmaceuticals to Present at Oppenheimer&#8217;s 36th Annual Healthcare Life Sciences Conference"},"content":{"rendered":"<p style=\"text-align: justify;\"><img loading=\"lazy\" loading=\"lazy\" decoding=\"async\" src=\"https:\/\/api.newsfilecorp.com\/newsinfo\/284505\/511\" width=\"2\" height=\"2\" \/><\/p>\n<p style=\"text-align: justify;\">Encinitas, California&#8211;(Newsfile Corp. &#8211; February 19, 2026) &#8211; <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/ej014cM8q4\">Kiora Pharmaceuticals, Inc.<\/a> (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET.<\/p>\n<p style=\"text-align: justify;\">A live webcast will be available on Kiora&#8217;s investor relations website, <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/87DeAHO4qG\">ir.kiorapharma.com<\/a>, on the IR homepage and under the News &amp; Events section. A replay of the webcast will be available for approximately 90 days.<\/p>\n<p style=\"text-align: justify;\"><b>About Kiora Pharmaceuticals<\/b><br \/>\nKiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH). KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and\/or age-related retinal degeneration.<\/p>\n<p style=\"text-align: justify;\">In addition to news releases and SEC filings, we expect to post information on our website, <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/y4KB3Cbo3W\">www.kiorapharma.com<\/a>, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and\/or subscribe to email alerts.<\/p>\n<div style=\"text-align: justify;\">\n<p><b>Contacts:<\/b><br \/>\n<b>Investors<\/b><br \/>\n<a href=\"mailto:investors@kiorapharma.com\">investors@kiorapharma.com<\/a><\/p>\n<\/div>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/images.newsfilecorp.com\/files\/8481\/284505_46a34ad674b1eb3d_logo.jpg\" alt=\"Corporate Logo\" \/><\/p>\n<p style=\"text-align: justify;\">To view the source version of this press release, please visit <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/1KYWzTRNzz\">https:\/\/www.newsfilecorp.com\/release\/284505<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Encinitas, California&#8211;(Newsfile Corp. &#8211; February 19, 2026) &#8211; Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET. A live webcast will be available on Kiora&#8217;s investor relations website, ir.kiorapharma.com, on the IR homepage and [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":106422,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[54732],"tags":[],"class_list":["post-62398","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases"],"_links":{"self":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/62398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=62398"}],"version-history":[{"count":0,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/62398\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media\/106422"}],"wp:attachment":[{"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=62398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=62398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=62398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}